North America Alzheimers Disease Diagnostics Market Size & Outlook
The alzheimers disease diagnostics market in North America is expected to reach a projected revenue of US$ 9,971.6 million by 2033. A compound annual growth rate of 10.9% is expected of North America alzheimers disease diagnostics market from 2026 to 2033.
In terms of revenue, North America region accounted for 47.5% of the global alzheimers disease diagnostics market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 3,253.6 million by 2033.
North America dominated the Alzheimer’s disease diagnostics market in 2024 and is expected to maintain this position over the forecast period. This high share is attributable to the presence of key players in the market, such as LabCorp, Quanterix, Sysmex, and other players.
Moreover, growth of the market can majorly be attributed to the increasing prevalence of Alzheimer’s disease in the region. For instance, according to an article published by the National Library of Medicine, in April 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer's dementia.
This number is projected to rise to 13.8 million by 2060 unless medical breakthroughs occur to prevent, slow, or cure Alzheimer’s disease. Furthermore, North America is at the forefront of research for Alzheimer’s disease biomarkers, including cerebrospinal fluid analysis and blood-based biomarkers.
North America Alzheimers Disease Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Alzheimers Disease Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Imaging Techniques was the largest segment with a revenue share of 44.6% in 2025.
Horizon Databook has segmented the North America alzheimers disease diagnostics market based on biomarkers, imaging techniques, genetic testing, cognitive assessment tests covering the revenue growth of each sub-segment from 2021 to 2033.
North America dominated the Alzheimer’s disease diagnostics market in 2024 and is expected to maintain this position over the forecast period. This high share is attributable to the presence of key players in the market, such as LabCorp, Quanterix, Sysmex, and other players.
Moreover, growth of the market can majorly be attributed to the increasing prevalence of Alzheimer’s disease in the region. For instance, according to an article published by the National Library of Medicine, in April 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer's dementia.
This number is projected to rise to 13.8 million by 2060 unless medical breakthroughs occur to prevent, slow, or cure Alzheimer’s disease. Furthermore, North America is at the forefront of research for Alzheimer’s disease biomarkers, including cerebrospinal fluid analysis and blood-based biomarkers.
North America Alzheimers Disease Diagnostics Market Diagnostic Technique Outlook (Revenue, USD Million , 2021-2033)
Biomarkers
Imaging Techniques
Genetic Testing
Cognitive Assessment Tests
North America Alzheimers Disease Diagnostics Market Type Outlook (Revenue, USD Million , 2021-2033)
Triage
Diagnosis
Screening
North America Alzheimers Disease Diagnostics Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals
Diagnostic Laboratories
Academic and Research Institutes
Reasons to subscribe to Alzheimers Disease Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Alzheimers Disease Diagnostics Market Outlook databook
Our clientele includes a mix of Alzheimers Disease Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Alzheimers Disease Diagnostics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Alzheimers Disease Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Alzheimers Disease Diagnostics Market, 2021-2033 (US$M)